Advisory Services Network’s Quince Therapeutics QNCX Stock Holding History

Advisory Services Network’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28	Closed	-$558	–	4054
2026 Q1	$558	Buy	+28	New	+$5.62K	﹤0.01%	4406
2025 Q4	–	Sell	-28	Closed	-$8.96K	–	3685
2025 Q3	$8.96K	Buy	+28	New	+$9.32K	﹤0.01%	3330
2024 Q1	–	Sell	-5	Closed	-$1.1K	–	3140
2023 Q4	$1.1K	Buy	+5	New	+$1K	﹤0.01%	3513
2023 Q2	–	Sell	-5	Closed	-$1.64K	–	3124
2023 Q1	$1.64K	Hold	5	–	–	﹤0.01%	3491
2022 Q4	$669	Buy	+5	New	+$836	﹤0.01%	3687
2021 Q3	–	Sell	-1	Closed	-$5K	–	2791
2021 Q2	$5K	Buy	+1	New	+$8.38K	﹤0.01%	3084
2021 Q1	–	Hold	0	–	-$1K	–	2563
2020 Q4	–	Hold	0	–	–	–	3177
2020 Q3	–	Hold	0	–	–	–	2991
2020 Q2	–	Hold	0	–	-$2K	–	2342
2020 Q1	–	Hold	0	–	–	–	2778
2019 Q4	–	Hold	0	–	–	–	2993

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Advisory Services Network's QNCX Position: Q2 2026 in Review

Advisory Services Network sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 28 shares — an estimated $558 sold.

Advisory Services Network first reported a position in QNCX in Q2 2021 and held it in 6 quarters. The position peaked at $8.96K in Q3 2025. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

Advisory Services Network reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 28 Quince Therapeutics shares in Q2 2026, an estimated $558.
Advisory Services Network first reported a position in Quince Therapeutics in Q2 2021 and held it in 6 quarters.
Advisory Services Network's Quince Therapeutics position peaked at $8.96K in Q3 2025.
27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.